By Vivonyx · Last reviewed: October 2026
If you live with CIDP, or love someone who does, you may have seen the phrase "stem cell transplant" in a support group or a headline. The question behind it is a fair one: what does the research actually show about stem cell transplants for CIDP?
This article walks through the human studies, what they measured, and where the evidence runs out. It's education, not medical advice, and it isn't a recommendation for or against anything.
CIDP in one minute
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a nerve condition in which the immune system attacks myelin, the protective coating around peripheral nerves. Common symptoms include weakness and reduced feeling in the arms and legs [1].
Most people are managed with standard immune therapies. A 2021 European guideline strongly recommends immunoglobulin (IVIg) or corticosteroids first, and plasma exchange if those don't work [2]. Not everyone responds well enough, and some people need these therapies long term [3][4]. That smaller group is where transplant research comes in.
Two very different meanings of "stem cells"
The word "stem cells" covers two quite different things in CIDP discussions:
Autologous hematopoietic stem cell transplant (HSCT). A person's own blood-forming stem cells are collected, then strong chemotherapy and antibody drugs are given to deeply suppress the immune system. The stored cells are then returned so the blood and immune system can rebuild [5][6]. Researchers describe the goal as "immune reconstitution" [7], not nerve repair by the cells themselves.
Mesenchymal stromal cell (MSC) injections. These are a different cell type, usually from fat, bone marrow, or umbilical cord tissue. For CIDP, they have barely been studied in people (more on that below).
Almost all of the published human CIDP research we found is on HSCT. Our MSC neuropathy article and our diabetic neuropathy article cover MSC research in other nerve conditions.
The main human studies of stem cell transplant for CIDP. Educational summary of the sources cited in this article.
What the CIDP transplant studies found
The short version: the reported results are positive, but every study was small and none was randomized.
Sweden (11 people). In people whose CIDP hadn't responded to first-line and, in most cases, other therapies, disability scores improved after transplant. At a median follow-up of 28 months, 8 of 11 were in drug-free remission and 3 had relapsed [3]. The authors noted the small size and lack of a control group, and called for randomized trials [3].
United States (60 people analyzed). In a study of people who depended on IVIg or plasma exchange, 76% to 83% were off immune drugs at each yearly check over 5 years. Walking without help rose from 33% before transplant to 81% to 86% afterward, and nerve test results improved [5]. There were no treatment-related deaths. The authors said a randomized trial is needed to confirm the results [5].
Canada (5 people). All 5 were able to stop CIDP immunotherapy, and 4 of 5 improved markedly on strength and disability scales. One person with long-standing nerve damage did not improve [8].
Australia (3 people with CIDP). A small trial of transplant for several immune conditions of the nervous system included 3 people with CIDP. Across all 12 people, 5 were relapse-free at a median of 36 months, and the authors called the evidence for these conditions "scant" [7].
Why does a comparison group matter? CIDP can change over time, and some people in these studies relapsed. Without a control group, it's hard to know how much of any change came from the transplant itself.
Get the next article in your inbox
One short email when a new research article goes up. No spam, unsubscribe anytime.
What reviews and expert groups say
A 2023 meta-analysis pooled 89 people from 11 studies. About 81% were free of all immune drugs afterward. The authors suggested HSCT may be an option for refractory CIDP "when carefully evaluated," while noting the risks [9].
European transplant guidelines (2020) list CIDP among conditions where HSCT "may have a potential role." They stress that HSCT carries greater short-term risks than other immune therapies and should happen in accredited transplant centers with neurologists and transplant doctors working together. Other experimental cell therapies, they add, should only be given in clinical trials [6].
A 2024 review of CIDP therapies describes HSCT as "rarely considered" and supported mainly by case series [4].
A 2024 chapter by transplant researchers warns that a significant number of people labeled with CIDP turn out to have a different nerve condition on further testing, so the diagnosis should be confirmed before transplant [10].
The risks are real
HSCT is an intensive procedure done in transplant centers, not a simple injection [6]. In the Swedish series, short-term problems included reactivation of viruses such as CMV and Epstein-Barr virus, CMV disease, bladder bleeding (hemorrhagic cystitis), and pancreatitis [3]. Expert guidelines describe greater short-term risks than other immune therapies [6]. The studies above included only people whose CIDP hadn't responded well to standard care or depended on it [3][5][9].
What about MSC injections for CIDP?
Here the evidence is thin. A ClinicalTrials.gov listing describes a single-patient expanded-access program giving a person's own fat-derived MSCs for CIDP; its status is "no longer available" [11]. We did not find published controlled trials of MSCs for CIDP. European guidelines say experimental cell therapies for these conditions belong in clinical trials [6].
FDA status and clinical trials
The FDA says the only FDA-approved stem cell products are blood-forming stem cells from umbilical cord blood, approved for certain disorders of blood production [12]. It also says regenerative medicine products have not been approved to treat any neurological disorder [13]. The FDA has received reports of blindness, tumor formation, and infections linked to unapproved products [13]. Our guide Is Stem Cell Therapy FDA Approved? explains what approval means.
A ClinicalTrials.gov search for CIDP and stem cells returns 3 U.S. listings [14]: the completed U.S. phase II transplant study [15], a phase II transplant study for several immune nerve conditions, listed as active but not recruiting [16], and the single-patient MSC program above [11]. The FDA cautions that a ClinicalTrials.gov listing doesn't, by itself, mean a product is legally marketed [13].
What we still don't know
How HSCT compares with standard care. No randomized trial has compared it with ongoing immune therapy [9][3].
Who is most likely to benefit. Results depend on the right diagnosis and the right stage of disease [10].
Which transplant method is best. Centers used different drug combinations before transplant [5][16].
Whether MSCs have any role. There is almost no human research [11].
Frequently asked questions
Can a stem cell transplant help CIDP? Small studies of autologous HSCT have reported that many people with hard-to-manage CIDP improved and stopped immune drugs, but there are no randomized trials yet [9][5].
Is stem cell transplant for CIDP the same as a stem cell injection? No. HSCT uses strong chemotherapy and a person's own blood-forming stem cells to rebuild the immune system. MSC injections are a different cell type and have barely been studied in CIDP [6][11].
Who has been included in CIDP transplant studies? People whose CIDP did not respond well to, or depended on, standard therapies such as IVIg, steroids, or plasma exchange [3][5].
What are the risks of HSCT for CIDP? Studies report infections and virus reactivation, among other short-term problems. Guidelines say the short-term risks are greater than with other immune therapies [3][6].
Is stem cell therapy FDA-approved for CIDP? No. The FDA says regenerative medicine products have not been approved to treat any neurological disorder [13].
Still have questions?
If you'd like help reading a study or a trial listing, email hello@vivonyx.com or use our Ask page. We'll give you a straight answer, including "the research doesn't know yet" when that's the truth.
Related reading
Educational disclaimer: This article is for general educational purposes only and is not medical advice, diagnosis, or treatment. It does not describe or suggest the treatment, cure, or prevention of any disease or condition. Regulatory status can change; check the cited FDA pages for current information. Talk with a qualified, licensed healthcare professional before making any medical decision.
References
National Institute of Neurological Disorders and Stroke (NINDS). Peripheral Neuropathy. https://www.ninds.nih.gov/health-information/disorders/peripheral-neuropathy
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force - second revision. Eur J Neurol. 2021;28(11):3556-3583. PMID: 34327760. https://pubmed.ncbi.nlm.nih.gov/34327760/
Press R, Askmark H, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP. J Neurol Neurosurg Psychiatry. 2014;85(6):618-624. PMID: 24262917. https://pubmed.ncbi.nlm.nih.gov/24262917/
Rajabally YA. Chronic inflammatory demyelinating polyradiculoneuropathy: current therapeutic approaches and future outlooks. Immunotargets Ther. 2024;13:99-110. PMID: 38435981. https://pubmed.ncbi.nlm.nih.gov/38435981/
Burt RK, Balabanov R, Tavee J, et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 2020;267(11):3378-3391. PMID: 32594300. https://pubmed.ncbi.nlm.nih.gov/32594300/
Sharrack B, Saccardi R, Alexander T, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020;55(2):283-306. PMID: 31558790. https://pubmed.ncbi.nlm.nih.gov/31558790/
Nitz C, Withers B, Ma DDF, et al. Autologous haematopoietic stem cell transplantation in non-MS neuroimmunological diseases. Mult Scler Relat Disord. 2025;103:106714. PMID: 40945470. https://pubmed.ncbi.nlm.nih.gov/40945470/
Masson-Roy J, Breiner A, Warman-Chardon J, et al. Autologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. Can J Neurol Sci. 2021;48(6):760-766. PMID: 33631093. https://pubmed.ncbi.nlm.nih.gov/33631093/
Zheng Y, Hu J, Sun C, et al. Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. Eur J Neurol. 2023;30(8):2570-2582. PMID: 37170791. https://pubmed.ncbi.nlm.nih.gov/37170791/
Burt RK, Burman J, Barker A, Sharrack B. Hematopoietic stem cell transplantation (HSCT) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): is it CIDP? Handb Clin Neurol. 2024;202:199-238. PMID: 39111908. https://pubmed.ncbi.nlm.nih.gov/39111908/
ClinicalTrials.gov. NCT04825626: An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). https://clinicaltrials.gov/study/NCT04825626
U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
ClinicalTrials.gov (U.S. National Library of Medicine). Search: CIDP, stem cell. https://clinicaltrials.gov/search?cond=CIDP&intr=stem%20cell
ClinicalTrials.gov. NCT00278629: Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy. https://clinicaltrials.gov/study/NCT00278629
ClinicalTrials.gov. NCT00716066: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases. https://clinicaltrials.gov/study/NCT00716066